Delayed remote ischemic preconditioning produces an additive cardioprotection to sevoflurane postconditioning through an enhanced heme oxygenase 1 level partly via nuclear factor erythroid 2-related factor 2 nuclear translocation

J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):558-66. doi: 10.1177/1074248414524479. Epub 2014 Mar 19.

Abstract

Although both sevoflurane postconditioning (SPoC) and delayed remote ischemic preconditioning (DRIPC) have been proved effective in various animal and human studies, the combined effect of these 2 strategies remains unclear. Therefore, this study was designed to investigate this effect and elucidate the related signal mechanisms in a Langendorff perfused rat heart model. After 30-minute balanced perfusion, isolated hearts were subjected to 30-minute ischemia followed by 60-minute reperfusion except 90-minute perfusion for control. A synergic cardioprotective effect of SPoC (3% v/v) and DRIPC (4 cycles 5-minute occlusion/5-minute reflow at the unilateral hindlimb once per day for 3 days before heart isolation) was observed with facilitated cardiac functional recovery and decreased cardiac enzyme release. The infarct size-limiting effect was more pronounced in the combined group (6.76% ± 2.18%) than in the SPoC group (16.50% ± 4.55%, P < .001) or in the DRIPC group (10.22% ± 2.57%, P = .047). Subsequent analysis revealed that an enhanced heme oxygenase 1 (HO-1) expression, but not protein kinase B/AKt or extracellular signal-regulated kinase 1 and 2 activation, was involved in the synergic cardioprotective effect, which was further confirmed in the messenger RNA level of HO-1. Such trend was also observed in the nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translocation, an upstream regulation of HO-1. In addition, correlation analysis showed a significantly positive relationship between HO-1 expression and Nrf2 translocation (r = 0.729, P < .001). Hence, we conclude that DRIPC may produce an additive cardioprotection to SPoC through an enhanced HO-1 expression partly via Nrf2 translocation.

Keywords: Nrf2; cardioprotection; combination; delayed remote ischemic preconditioning; heme oxygenase 1; sevoflurane postconditioning.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Active Transport, Cell Nucleus / drug effects
  • Animals
  • Cardiotonic Agents / pharmacology*
  • Cytoprotection
  • Disease Models, Animal
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Heme Oxygenase (Decyclizing) / genetics
  • Heme Oxygenase (Decyclizing) / metabolism*
  • Hindlimb
  • In Vitro Techniques
  • Ischemic Preconditioning / methods*
  • Male
  • Methyl Ethers / pharmacology*
  • Muscle, Skeletal / blood supply*
  • Myocardial Infarction / enzymology
  • Myocardial Infarction / genetics
  • Myocardial Infarction / pathology
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / prevention & control*
  • Myocardial Reperfusion Injury / enzymology
  • Myocardial Reperfusion Injury / genetics
  • Myocardial Reperfusion Injury / pathology
  • Myocardial Reperfusion Injury / physiopathology
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardium / enzymology*
  • Myocardium / pathology
  • NF-E2-Related Factor 2 / metabolism*
  • Perfusion
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt / metabolism
  • RNA, Messenger / metabolism
  • Rats, Sprague-Dawley
  • Sevoflurane
  • Signal Transduction / drug effects
  • Time Factors

Substances

  • Cardiotonic Agents
  • Methyl Ethers
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, rat
  • RNA, Messenger
  • Sevoflurane
  • Heme Oxygenase (Decyclizing)
  • Hmox1 protein, rat
  • Proto-Oncogene Proteins c-akt
  • Extracellular Signal-Regulated MAP Kinases